Michael Holyoak, DO
Endocrinology, Diabetes & Metabolism · Meridian, IDNPI 1679968051
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,412 of the $2,205 with a category attached, or 64.0%. Amgen accounts for 66.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $1,529 and has fallen 93.1% since, to $105 in 2025.
Across 26 payments — averaging $84.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Tandem Diabetes Care, Inc.$353
- Ascendis Pharma Endocrinology Inc$125
- Abbott$71
- Insulet Corporation$46
- Medtronic$34
- plus $115 from 6 others
What the payments were for
- Speaking & faculty fees$1,41264%
- Food & beverage$79336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 4 | $1,460 |
| Tandem Diabetes Care, Inc. | 6 | $353 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Abbott | 4 | $71 |
| Insulet Corporation | 2 | $46 |
| Medtronic | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Novo Nordisk | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,412
- t:slim X2 Insulin Pump with Control-IQ$230
- Yorvipath$125
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 26 | $1,219,611 |
| MounjaroTirzepatide | 77 | $101,055 |
| TymlosAbaloparatide | 29 | $75,671 |
| Repatha SureclickEvolocumab | 51 | $41,367 |
| TrulicityDulaglutide | 34 | $39,215 |
| JardianceEmpagliflozin | 25 | $35,070 |
| OzempicSemaglutide | 24 | $29,543 |
| GenotropinSomatropin | 13 | $22,277 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $21,212 |
| NexletolBempedoic Acid | 14 | $17,308 |
| BaqsimiGlucagon | 31 | $15,894 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $10,580 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $9,675 |
| Cabergoline | 21 | $8,772 |
| NovologInsulin Aspart | 23 | $8,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Insulin Lispro | $33 | $158,718158 claims |
| Novo NordiskOzempic, Novolog | $23 | $37,55147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Meridian
- Robert EnnisMeridian$69K
- Johannes VeldhuisMeridian$80
- Lynn Ge-ZerbeMeridian$0
- Theodore RooseveltBoise$65K
- David LiljenquistIdaho Falls$9K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.